Unique ID issued by UMIN | UMIN000019287 |
---|---|
Receipt number | R000022298 |
Scientific Title | Antihypertensive therapy of bevacizumab-induced hypertension. |
Date of disclosure of the study information | 2015/10/08 |
Last modified on | 2019/01/18 08:51:48 |
Antihypertensive therapy of bevacizumab-induced hypertension.
Antihypertensive therapy of bevacizumab-induced hypertension.
Antihypertensive therapy of bevacizumab-induced hypertension.
Antihypertensive therapy of bevacizumab-induced hypertension.
Japan |
Hypertension
Cardiology |
Others
NO
Hypotensive effect of antihypertensive agent for bevacizumab induced hypertension is unclear. This study aimed to describe the efficacy of antihypertensive agent for Bevacizumab-induced hypertension in cancer patients treated with Bevacizumab.
Safety,Efficacy
The primary endpoint is home blood pressure control ratio at three weeks after initiation of treatment with an antihypertensive agent.
The secondary endpoint is
1)Change of the home blood pressure due to treatment with antihypertensive agent for Bevacizumab-induced hypertension.
2)Change of the office blood pressure due to treatment with antihypertensive agent for Bevacizumab-induced hypertension.
3)adverse event due to treatment with antihypertensive agent for Bevacizumab-induced hypertension.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1)Pathologically confirmation of cancer.
2)Administration of bevacizumab (15mg/kg) is planned.
3)No prior therapy of anti-VEGF antibody drug.
4)No prior therapy of antihypertensive drug.
5)Written informed consent.
1)Renal failure (Cre>=1.5mg/dL)
56
1st name | |
Middle name | |
Last name | Kei Iida |
Shizuoka Cancer Center
Division of Cardiology
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
(+81)055-989-5222
k.iida@scchr.jp
1st name | |
Middle name | |
Last name | Takuya Oyakawa |
Shizuoka Cancer Center
Division of Cardiology
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
(+81)055-989-5222
t.oyakawa@scchr.jp
Shizuoka Cancer Center
Shizuoka Cancer Center
Other
NO
2015 | Year | 10 | Month | 08 | Day |
Unpublished
Terminated
2015 | Year | 03 | Month | 02 | Day |
2015 | Year | 10 | Month | 08 | Day |
Prospective observational study
We monitor the home and office blood pressure of the patients receiving Bevacizumab. When patients develop Bevacizumab-induced hypertension, we initiate treatment with an antihypertensive drug.
2015 | Year | 10 | Month | 08 | Day |
2019 | Year | 01 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022298
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |